Walter Stadler, MD, is an expert in prostate, kidney, bladder, and testicular cancers. He concentrates on the use of chemotherapy, immunotherapy, anti-angiogenic therapy, and molecularly targeted therapy for patients with locally advanced or metastatic disease.
His research focuses on the development of new treatments for these urological cancers. Dr. Stadler's research includes development of molecular and imaging markers for predicting response to various anti-cancer therapies.
Dr. Stadler has authored and co-authored more than 200 articles in medical journals such as Cancer Research and the Journal of Clinical Oncology, in addition to more than 100 book chapters, reviews, letters, and editorials. He is an active member of several committees and boards, including the medical advisory boards of the Kidney Cancer Association and the Bladder Cancer Advocacy Network, and the editorial board of UpToDate in Oncology, an information source for oncologists.
Specialties
Areas of Expertise
- Renal Cancer
- Bladder Cancer
- Prostate Cancer
- Testicular Cancer
- Kidney Cancer
Board Certifications
- Medical Oncology
Memberships & Medical Societies
- American College of Physicians
- American Federation for Medical Research
- American Association for Cancer Research
- American Association for the Advancement of Science
- American Urological Association
- American Society of Clinical Oncology
- Society of Urologic Oncology
Practicing Since
- 1994
Languages Spoken
- English
- German
Medical Education
- Yale University
Internship
- Michael Reese Hospital
Residency
- Michael Reese Hospital
Fellowship
- University of Chicago Medicine
News & Research
View Published Papers- Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors
- Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, the RadiCaL Study
- Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
- A Study of Tarlatamab (AMG 757) in Participants With Neuroendocrine Prostate Cancer
- Effect of Education on Treatment Decision Making for Patients With Prostate Cancer on Chronic Hormone Treatments
- A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients
- Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
- A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)
- CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone
- Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors
- Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
- Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
- Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors
- S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery
- A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
- Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)
- Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer
- Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
- Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed
- Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
- Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer
- Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2
- sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
- Aetna HMO (specialists only)
- Aetna POS
- Aetna PPO
- BCBS Blue Precision HMO (specialists only)
- BCBS HMO (HMOI) (specialists only)
- BCBS PPO
- Cigna HMO
- Cigna POS
- Cigna PPO
- CountyCare *see insurance page
- Aetna Better Health *see insurance page
- Medicare
- Multiplan PPO
- PHCS PPO
- United Choice Plus POS/PPO
- United Options (PPO)
- United Select (HMO & EPO) (specialists only)
- United W500 Emergent Wrap
- Aetna Medicare Advantage HMO & PPO
- BCBS Medicare Advantage HMO & PPO
- Humana Medicare Advantage Choice PPO
- Humana Medicare Advantage Gold Choice PFFS
- Humana Medicare Advantage Gold Plus HMO
- United Choice HMO (specialists only)
- University of Chicago Health Plan (UCHP)
Our list of accepted insurance providers is subject to change at any time. You should contact your insurance company to confirm UChicago Medicine participates in their network before scheduling your appointment. If your insurance company is not listed here, or if you have any other questions, please contact Managed.Care@uchospitals.edu.
Duchossois Center for Advanced Medicine (DCAM) - Hyde Park
Request an Appointment at Duchossois Center for Advanced Medicine (DCAM) - Hyde Park
To Refer a Patient
Refer a Patient